Dishevelled 2 regulates cancer cell proliferation and T cell mediated immunity in HER2-positive breast cancer

被引：0
|
作者：
Fahmida Rasha
Geetha Priya Boligala
Mingxiao V. Yang
Dalia Martinez-Marin
Isabel Castro-Piedras
Kathryn Furr
Annie Snitman
Sonia Y. Khan
Luis Brandi
Maribel Castro
Hafiz Khan
Nusrat Jahan
Sharilyn Almodovar
Michael W. Melkus
Kevin Pruitt
Rakhshanda Layeequr Rahman
机构：
[1] Texas Tech University Health Sciences Center,Department of Immunology and Molecular Microbiology
[2] Texas Tech University Health Sciences Center,Depart of Cell Biology and Biochemistry
[3] Texas Tech University Health Sciences Center,Department of Surgery
[4] School of Medicine,Breast Center of Excellence
[5] Texas Tech University Health Sciences Center,Department of Pathology
[6] Texas Tech University Health Sciences Center,Department of Public Health, Julia Jones Matthews
[7] Texas Tech University Health Sciences Center,Department of Medicine
[8] Texas Tech University Health Sciences Center,undefined
来源：
BMC Cancer | / 23卷
关键词：
Breast cancer; Dishevelled; HER2; Tumor infiltrating lymphocytes; Wnt signaling;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Dishevelled 2 regulates cancer cell proliferation and T cell mediated immunity in HER2-positive breast cancer
    Rasha, Fahmida
    Boligala, Geetha Priya
    Yang, Mingxiao V.
    Martinez-Marin, Dalia
    Castro-Piedras, Isabel
    Furr, Kathryn
    Snitman, Annie
    Khan, Sonia Y.
    Brandi, Luis
    Castro, Maribel
    Khan, Hafiz
    Jahan, Nusrat
    Almodovar, Sharilyn
    Melkus, Michael W.
    Pruitt, Kevin
    Rahman, Rakhshanda Layeequr
    BMC CANCER, 2023, 23 (01)
  • [2] Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells
    Schmucker, Hannah
    Blanding, Walker M.
    Mook, Julia M.
    Wade, Jessica F.
    Park, Jang Pyo
    Kwist, Kerri
    Shah, Hiral
    Booth, Brian W.
    CELLULAR ONCOLOGY, 2018, 41 (02) : 159 - 168
  • [3] Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells
    Hannah Schmucker
    Walker M. Blanding
    Julia M. Mook
    Jessica F. Wade
    Jang Pyo Park
    Kerri Kwist
    Hiral Shah
    Brian W. Booth
    Cellular Oncology, 2018, 41 : 159 - 168
  • [4] Radiosensitization of HER2-positive breast cancer cell lines with trastuzumab
    Alanyali, Senem Demirci
    Bozkurt, Emir
    Alanyali, Hilmi
    Karaca, Burcak
    Uslu, Ruchan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [6] Quantitative analysis of T cell and macrophage immune markers in Her2-positive breast cancer
    Shiao, S. L.
    Gertych, A.
    Ma, Z.
    Zhang, X.
    Burnison, C. M.
    Mirhadi, A. J.
    Giuliano, A.
    Knudsen, B. S.
    Chung, A.
    CANCER RESEARCH, 2016, 76
  • [7] Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines
    Dostalova, Hana
    Jorda, Radek
    Reznickova, Eva
    Krystof, Vladimir
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (02) : 210 - 219
  • [8] Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines
    Hana Dostálová
    Radek Jorda
    Eva Řezníčková
    Vladimír Kryštof
    Investigational New Drugs, 2023, 41 : 210 - 219
  • [9] Inflammatory HER2-positive breast cancer
    Dirix, Luc Y.
    Vermeulen, Peter B.
    LANCET ONCOLOGY, 2012, 13 (04): : 324 - 326
  • [10] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
12345